The spinout has revealed it added approximately $6m to a series A round backed by University of Pennsylvania and IP Group last year, bringing its total size to about $59m.

Carisma Therapeutics, a US-based immunotherapy spinout of University of Pennsylvania, has increased a series A round backed by commercialisation firm IP Group to approximately $59m, Technically Philly reported on Thursday. The company secured approximately $6m in an extension towards the end of 2018, according to chief executive Steven Kelly. He did not reveal the identity…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.